Femtobiomed

Developing an intracellular delivery platform for cell therapeutics

placeSeongnam-si, Gyeonggi-do, South Korea calendar_todayFounded 2016 groups14 employees language femtobiomed.com

Innovation

10 patent families (5 granted) — focus: Chemistry & metallurgy, Physics & computing, Human necessities; filing pace slowing. Cited 150 times.

YearFilings
20185
20192
20205
20214
20221
20241
20251

Investor mix

6 investors on record; lead investors include Aju IB Investment, Knet Investment Partners.

Investor typeCountShare
Venture capital350%
Private equity117%
Accelerator & incubator117%
Bank & private debt117%
Coming soon